Sugammadex dosing based on ideal or actual body weight in underweight patients.
Phase 1
Recruiting
- Conditions
- Patients undergoing general anesthesia
- Registration Number
- JPRN-jRCT1031230452
- Lead Sponsor
- Sato Hanae
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
BMI below 18.5
ASA-PS= 1-3
Exclusion Criteria
ppatient who is allergic to muscle relaxants
patient who has neuromuscular diseases
patient who has moderate to severe liver function failure
Patients with hypoalbuminemia
Patients taking medications that affect the muscle relaxant effect
Patients who are deemed inappropriate as research subjects by the principal investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time from sugammadex administration to TOFR=90%.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does Sugammadex's molecular mechanism differ when dosed by ideal vs actual body weight in underweight patients?
What is the comparative efficacy of Sugammadex dosing strategies in underweight patients versus standard-of-care reversal agents?
Which pharmacokinetic biomarkers predict optimal Sugammadex dosing in underweight patients with neuromuscular blockade?
What adverse event profiles are associated with Sugammadex in underweight patients, and how do they compare to neostigmine?
How does Sugammadex's reversal efficiency in underweight patients compare to other steroidal neuromuscular blocking agents?